Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
Reid W. Merryman(Harvard University), Ann S. LaCasce(Otsuka (Japan)), Jeremy S. Abramson(Massachusetts General Hospital), Justin Kline(University of Chicago), Robert Redd(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Margaret A. Shipp(Broad Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Erin M. Parry(Broad Institute), Philippe Armand(Harvard University), Inhye E. Ahn(Dana-Farber Cancer Institute), Scott J. Rodig(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), H.J. Lee(Dana-Farber Cancer Institute), Christine E. Ryan(Dana-Farber Cancer Institute), Kathleen L. Pfaff(Dana-Farber Cancer Institute), Eric D. Jacobsen(Dana-Farber Cancer Institute), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Mikaela M. McDonough(Dana-Farber Cancer Institute), Emma L. Welsh(Brigham and Women's Hospital)
Cited by 3
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k